CSL Enters $1.6 Billion Deal with Alentis Therapeutics for Experimental Kidney and Liver Drug
CSL has entered into a global partnership with Alentis Therapeutics to develop lixudebart, an experimental antibody targeting serious kidney and liver diseases. The deal includes an upfront payment of $355 million from CSL to Alentis. Additionally, Alentis could receive up to another $1.2 billion in potential future payments tied to development milestones or commercial success. The partnership highlights CSL's strategic focus on expanding its portfolio into innovative therapies for critical unmet medical needs. Lixudebart is currently under investigation and represents a significant investment in the biotech sector, signaling confidence in Alentis' research capabilities.
Tickers: $CSLLY